Recent Updates
Recently added Catalysts
TAK Positive Sentiment

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1

Thursday, October 15, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Takeda has launched ORZEYFUL (oveporexton) in Japan and China for treating narcolepsy type 1. This first-in-class orexin receptor 2 agonist offers a novel approach to address the orexin deficiency in patients. The launch provides clinicians with the first opportunity to prescribe this innovative treatment, potentially improving patient outcomes.

Market Sentiment Analysis

POSITIVE FACTORS

  • Launch of ORZEYFUL provides new treatment options for narcolepsy type 1.
  • First-in-class orexin receptor 2 agonist addresses orexin deficiency.
  • Simultaneous launch in Japan and China enhances accessibility for patients.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+27%
120-day peak, hindsight
Typical move
1.6%
average across 15 past catalysts
Lead asset
NDI-034858 study drug
NDA/BLA · Moderate to Severe Plaque Psoriasis

Full Press Release Details

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re excited at the potential to fundamentally chan

Frequently Asked Questions

What is ORZEYFUL used for?

ORZEYFUL is used for treating narcolepsy type 1.

Where has ORZEYFUL been launched?

ORZEYFUL has been launched in Japan and China.

What type of drug is ORZEYFUL?

ORZEYFUL is a first-in-class orexin receptor 2 agonist.

What condition does ORZEYFUL address?

It addresses the orexin deficiency associated with narcolepsy type 1.

ShareAdd on Google
Tags: TAK Takeda ORZEYFUL oveporexton narcolepsy type 1 ox2r agonist
Last updated: Oct 15, 2026

Biotech snapshot

Lead asset
NDI-034858 study drugNDA/BLA
Moderate to Severe Plaque Psoriasis →

Catalyst track record

+27%
best trade around TAK's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for TAK.

See every catalyst's timing & PoA →